Dermatitis, Atopic trials in Chile: Trial Insights

Filters: Condition: Dermatitis, Atopic Country / region: Chile Clear all

19 trials match Source: ClinicalTrials.gov registrations

Trials started per year
Category	Trials
2009	1
2014	1
2018	4
2020	1
2021	1
2022	1
2023	5
2024	4
2026	1

Trials by status
Category	Trials
Completed	12
Active, not recruiting	5
Recruiting	1
Terminated	1

Top lead sponsors
Category	Trials
Sanofi	8
Pfizer	4
Pontificia Universidad Catolica de Chile	3
Amgen	2
AbbVie	1
Northwestern University	1

Top conditions
Category	Trials
Dermatitis, Atopic	19
Eczema	6
Hypersensitivity	3
Dermatitis	2
Genetic Diseases, Inborn	2
Hypersensitivity, Immediate	2
Immune System Diseases	2
Skin Diseases	2
Skin Diseases, Eczematous	2
Skin Diseases, Genetic	2

Trials

Showing 1 to 19 of 19. Each trial links to its page on Pharma Observatory.

Retention of Vernix Caseosa in Newborns for Primary Prevention of Atopic Dermatitis NCT07333378Not applicableRecruitingPontificia Universidad Catolica de ChileStarted 2026
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis NCT06461897Phase 3Active, not recruitingAbbVieStarted 2024
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis NCT06407934Phase 3Active, not recruitingSanofiStarted 2024
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor NCT06241118Phase 3Active, not recruitingSanofiStarted 2024
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids NCT06224348Phase 3CompletedSanofiStarted 2024
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2) NCT06181435Phase 3CompletedSanofiStarted 2023
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis NCT06130566Phase 3CompletedSanofiStarted 2023
A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) NCT05882877Phase 3TerminatedAmgenStarted 2023
A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) NCT05704738Phase 3CompletedAmgenStarted 2023
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis NCT05769777Phase 2Active, not recruitingSanofiStarted 2023
Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials NCT05492578Phase 2/3Active, not recruitingSanofiStarted 2022
Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis NCT05018806Phase 2CompletedSanofiStarted 2021
Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy NCT04345367Phase 3CompletedPfizerStarted 2020
Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy NCT03720470Phase 3CompletedPfizerStarted 2018
Early Origins of Allergy and Asthma NCT04186949ObservationalCompletedPontificia Universidad Catolica de ChileStarted 2018
Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects NCT03627767Phase 3CompletedPfizerStarted 2018
Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis NCT03422822Phase 3CompletedPfizerStarted 2018
Impact of Vitamin D Supplementation on Severity of Pediatric Atopic Dermatitis NCT01996423Not applicableCompletedPontificia Universidad Catolica de ChileStarted 2014
Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index NCT00879944ObservationalCompletedNorthwestern UniversityStarted 2009

A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis NCT06461897Status changeRecruiting to Active, not recruitingOctober 18, 2026
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis NCT06461897Enrollment change675 to 699October 18, 2026
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis NCT06461897Completion date change2030-07-31 to 2029-11-30October 18, 2026

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.

Visit Pharma Observatory